erlotinib hydrochloride has been researched along with arginine vasopressin in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (arginine vasopressin) | Trials (arginine vasopressin) | Recent Studies (post-2010) (arginine vasopressin) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 12,278 | 422 | 1,212 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | arginine vasopressin (IC50) |
|---|---|---|---|
| Vasopressin V2 receptor | Homo sapiens (human) | 0.242 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benveniste, MF; Carter, BW; de Groot, PM; Shroff, GS; Truong, MT; Viswanathan, C; Wu, CC | 1 |
1 review(s) available for erlotinib hydrochloride and arginine vasopressin
| Article | Year |
|---|---|
Imaging on Lung Cancer and Treatment with Targeted Therapy.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Antineoplastic Agents, Immunological; Arginine Vasopressin; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung; Lung Neoplasms; Mutation; Tomography, X-Ray Computed | 2018 |